Twist Bioscience Expands High-Throughput Antibody Characterization with Launch of Express Screening Antibodies
Business Wire•28/10/2026•08:00 ET
0
Key Highlights
- ➤Twist launches Express Screening Antibodies for high-throughput antibody characterization
- ➤Turnaround time begins at five days for purified antibody screening
- ➤Workflow enables assessment of thousands of antibodies per day
- ➤Cell-free offering delivers purified full-length IgG with SPR binding characterization
- ➤Twist supports full-length IgG, scFv-Fc, and VHH-Fc antibody formats
Expert Statements
Emily M. Leproust, CEO and co-founder of Twist Bioscience
“As AI-guided drug discovery approaches dramatically expand the range of antibody candidates researchers can explore, the ability to turn that breadth into experimental data becomes critical”
Emily M. Leproust, CEO and co-founder of Twist Bioscience
“Twist Express Screening Antibodies bring speed and scalability to early-stage characterization, enabling researchers to move broader candidate sets from sequence to data, iterate faster and focus downstream development resources on the antibodies with the greatest potential.”
Twist Bioscience Expands High-Throughput Antibody Characterization with Launch of Express Screening Antibodies
Enables high-throughput assessment of thousands of antibodies per day to support AI/ML-driven discovery workflows
Get started
Create a free account to read the full story.